danielle klinger

Mrs. danielle klinger


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
DKdanielle klinger
danielle klinger
BHBrian Hill
Brian Hill
NBNoam Barda
Noam Barda
EHEran Halperin
Eran Halperin
OGOfer N. Gofrit
Ofer N. Gofrit
HBHerve Bercovier
Herve Bercovier
Bacillus Calmette–Guerin (BCG) is a live attenuated form of Mycobacterium bovis that was developed 100 years ago as a vaccine against tuberculosis (TB) and has been used ever since to vaccinate children globally. It has also been used as the first-line treatment in patients with nonmuscle invasive bladder cancer (NMIBC), through repeated intravesical applications. Numerous studies have shown that BCG induces off-target immune effects in various pathologies. Accumulating data argue for the critical role of the immune system in the course of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). In this study, we tested whether repeated exposure to BCG during the treatment of NMIBC is associated with the risk of developing AD and PD. We presented a multi-center retrospective cohort study with patient data collected between 2000 and 2019 that included 12,185 bladder cancer (BC) patients, of which 2301 BCG-treated patients met all inclusion criteria, with a follow-up of 3.5 to 7 years. We considered the diagnosis date of AD and nonvascular dementia cases for BC patients. The BC patients were partitioned into those who underwent a transurethral resection of the bladder tumor followed by BCG therapy, and a disjoint group that had not received such treatment. By applying Cox proportional hazards (PH) regression and competing for risk analyses, we found that BCG treatment was associated with a significantly reduced risk of developing AD, especially in the population aged 75 years or older. The older population (≥75 years, 1578 BCG treated, and 5147 controls) showed a hazard ratio (HR) of 0.726 (95% CI: 0.529–0.996; p-value = 0.0473). While in a hospital-based cohort, BCG treatment resulted in an HR of 0.416 (95% CI: 0.203–0.853; p-value = 0.017), indicating a 58% lower risk of developing AD. The risk of developing PD showed the same trend with a 28% reduction in BCG-treated patients, while no BCG beneficial effect was observed for other age-related events such as Type 2 diabetes (T2D) and stroke. We attributed BCG’s beneficial effect on neurodegenerative diseases to a possible activation of long-term nonspecific immune effects. We proposed a prospective study in elderly people for testing intradermic BCG inoculation as a potential protective agent against AD and PD.

11 July 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
DKdanielle klinger
danielle klinger
IBIdo Blass
Ido Blass
Nadav RappoportNadav Rappoport
Nadav Rappoport
Michal LinialMichal Linial
Michal Linial
The COVID-19 pandemic that started in China has spread within 3 months to the entire globe. We tested the hypothesis that the vaccination against tuberculosis by Bacille Calmette–Guérin vaccine (BCG) correlates with a better outcome for COVID-19 patients. Our analysis covers 55 countries complying with predetermined thresholds on the population size and number of deaths per million (DPM). We found a strong negative correlation between the years of BCG administration and the DPM along with the progress of the pandemic, corroborated by permutation tests. The results from multivariable regression tests with 23 economic, demographic, health-related, and pandemic restriction-related quantitative properties, substantiate the dominant contribution of BCG years to the COVID-19 outcomes. The analysis of countries according to an age-group partition reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population (0–24 years). Furthermore, a strong correlation and statistical significance are associated with the degree of BCG coverage for the most recent 15 years, but no association was observed in these years for other broadly used vaccination protocols for measles and rubella. We propose that BCG immunization coverage, especially among the most recently vaccinated population, contribute to attenuation of the spread and severity of the COVID-19 pandemic.

29 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
DKdanielle klinger
danielle klinger
IBIdo Blass
Ido Blass
Nadav RappoportNadav Rappoport
Nadav Rappoport
Michal LinialMichal Linial
Michal Linial
COVID-19 has spread to 210 countries within 3 months. We tested the hypothesis that the vaccination with BCG correlates with a better outcome for COVID-19 patients. Our analysis covers 55 countries, complying with predetermined thresholds on population size and deaths per million (DPM). We found a strong negative correlation between the years of BCG administration and a lower DPM along with the pandemic progression in time. The results from multivariable regression tests with 22 economical, demographic, and health-related quantitative properties for each country substantiate the dominant contribution of BCG administration years to the COVID-19 outcomes. Analyzing countries according to an age-group partition reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population and mostly to recent years immunization. We propose that BCG immunization coverage, especially among the most recently vaccinated contributes to attenuation of the spread and severity of the COVID-19 pandemic. One Sentence Summary: BCG vaccination regimes and COVID-19 outcomes

17 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RRRoni Rasnic
Roni Rasnic
DKdanielle klinger
danielle klinger
Dan Ofer OferDan Ofer Ofer
Dan Ofer Ofer
YCYoav Comay
Yoav Comay
Michal LinialMichal Linial
Michal Linial
EBEitan Bachmat
Eitan Bachmat
Evidence suggests varied trends in mortality surrounding the holiday period. Most studies support an association between increased mortality rates and holidays. We compare the effect of the number of holiday days per week on the overall mortality rate in the Israeli population. Between 2000-2020, we see significantly reduced mortality rates in weeks containing national holidays. We observed the same trend in all-cause mortality during the 3-weeks COVID-19 pandemic lockdown. As the Israeli health care system, and hospitals especially, function near peak capacity year-round, we propose that reduced medical service utilization during holidays and the COVID-19 lockdown period might underlie the lower mortality rates.

7 June 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
DKdanielle klinger
danielle klinger
IBIdo Blass
Ido Blass
Nadav RappoportNadav Rappoport
Nadav Rappoport
Michal LinialMichal Linial
Michal Linial
COVID-19 pandemic that started in China has spread within 3 months to the entire globe. We tested the hypothesis that the vaccination against tuberculosis by BCG correlates with a better outcome for COVID-19 patients. Our analysis covers 55 countries complying with predetermined thresholds on the population size and number of deaths per million (DPM). We found a strong negative correlation between the years of BCG administration and the DPM along with the progress of the pandemic, corroborated by permutation tests. The results from multivariable regression tests with 23 economic, demographic, health-related, and pandemic restriction quantitative properties, substantiate the dominant contribution of BCG years to the COVID-19 outcomes. The analysis of countries according to an age-group partition reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population (0-24 years). Furthermore, a strong correlation and statistical significance are associated with the degree of BCG coverage for the most recent 15 years, but no association was observed in these years for other broadly used vaccination protocols for measles and rubella. We propose that BCG immunization coverage, especially among the most recently vaccinated contributes to attenuation of the spread and severity of the COVID-19 pandemic.